Monthly information on share capital and company voting rights

Cellectis (Euronext Growth: CLLS) published its monthly report on share capital and voting rights as of March 31, 2026.

Rhea-AI Summary

Cellectis (Euronext Growth: CLLS) published its monthly report on share capital and voting rights as of March 31, 2026. The company reports 100,590,994 total shares and 106,001,228 total voting rights (ISIN: FR0010425595).

For questions, investor and media contacts are provided by the company.

Argus Apr 8 session

+5.65% close to close Open Argus

Details

News Market Reaction – CLLS

In the Apr 8 session, CLLS gained 5.65%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with the company’s established pattern of transparent capital-structure reporting. This notice simply confirms 100,590,994 shares and 106,001,228 voting rights as of 03/31/2026. Any outsized move would have come against relatively light pre-news volume and within a stock already trading below its $3.44 200-day average, suggesting investors weighed this routine disclosure against broader biotech sentiment and existing financing flexibility under the active F-3 shelf.

Key Figures

Total shares: 100,590,994 Total voting rights: 106,001,228 Reference date: 03/31/2026

Total shares

100,590,994

Total number of shares in the capital as of 03/31/2026

Total voting rights

106,001,228

Total number of company voting rights as of 03/31/2026

Reference date

03/31/2026

Date of reported share capital and voting rights

Historical Context

5 past events · Latest: Mar 19

5 events

1. Mar 19

   Full-year earnings

   24h Move

   -4.0%

   Reported 2025 financials, clinical progress and cash runway into H2 2027.

2. Mar 12

   Earnings date set

   24h Move

   +2.7%

   Announced timing of Q4 and full-year 2025 results and investor call.

3. Mar 04

   Monthly capital update

   24h Move

   -2.4%

   Disclosed total shares and voting rights as of 02/28/2026.

4. Feb 04

   Monthly capital update

   24h Move

   -1.1%

   Reported share count and voting rights as of 01/31/2026.

5. Jan 08

   Strategy & catalysts

   24h Move

   -1.6%

   Outlined 2026 strategy, key trials, and expected clinical milestones.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

isin code, voting rights

2 terms

isin code financial

"Listing market: Euronext Growth ISIN code: FR0010425595"

An ISIN code is a unique identifier for a specific financial asset, like a stock or bond, similar to a product's barcode. It helps investors, traders, and banks quickly and accurately find and track that asset across different markets worldwide. This makes buying, selling, and managing investments more organized and reliable.

voting rights regulatory

"Total number of voting rights"

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, April 07, 2026 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
03/31/2026	100,590,994	106,001,228

For further information on Cellectis, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com 

Attachments

• Voting_Rights_PR_March_2026_EN

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Cellectis (CLLS) report on March 31, 2026?

Cellectis reported 100,590,994 total shares as of March 31, 2026. According to the company, this figure reflects the total number of shares in the capital for that reporting date and is published under applicable market regulation.

What were the total voting rights for Cellectis (CLLS) on March 31, 2026?

The company reported 106,001,228 total voting rights as of March 31, 2026. According to the company, this count represents all exercisable voting rights tied to the reported share capital on that date.

Where is Cellectis (CLLS) listed and what is its ISIN code?

Cellectis is listed on Euronext Growth and uses ISIN FR0010425595. According to the company, the listing market and ISIN are provided in the monthly disclosure of share capital and voting rights.

Who should investors contact for more information about Cellectis (CLLS) share capital?

Investors can contact Arthur Stril, Chief Financial Officer & Chief Business Officer, at the provided investor relations email. According to the company, investor and media contacts are listed for further queries.

How often does Cellectis (CLLS) publish share capital and voting rights information?

Cellectis publishes monthly information on share capital and voting rights under market regulations. According to the company, this disclosure is part of routine regulatory reporting and includes the reporting date and totals.